Table 4 Summary of participants with worsening any time postdose on individual domains of the Neuropsychiatric Inventory
Domain | 12 mg, n/m (%) | 40 mg, n/m (%) | Placebo, n/m (%) |
|---|---|---|---|
Delusions | 135/633 (21.3) | 124/632 (19.6) | 153/639 (23.9) |
Hallucinations | 84/633 (13.3) | 89/632 (14.1) | 79/639 (12.4) |
Agitation/aggression | 245/633 (38.7) | 258/632 (40.8) | 259/639 (40.5) |
Depression/dysphoria | 278/633 (43.9) | 333/632 (52.7) | 256/639 (40.1) |
Anxiety | 269/633 (42.5) | 270/632 (42.7) | 250/639 (39.1) |
Elation/euphoria | 66/633 (10.4) | 60/632 (9.5) | 62/639 (9.7) |
Apathy/indifference | 294/633 (46.4) | 297/632 (47.0) | 306/639 (47.9) |
Disinhibition | 159/633 (25.1) | 155/632 (24.5) | 128/639 (20.0) |
Irritability/lability | 244/633 (38.5) | 284/632 (44.9) | 244/639 (38.2) |
Aberrant motor behavior | 177/633 (28.0) | 188/632 (29.7) | 198/639 (31.0) |
Sleep and nighttime behavior disorders | 191/633 (30.2) | 225/632 (35.6) | 182/639 (28.5) |
Appetite and eating changes | 252/632 (39.9) | 255/631 (40.4) | 225/639 (35.2) |